1. Introduction {#sec1}
===============

Wilson\'s disease (WD) is a rare autosomal recessive disorder of copper metabolism.*ATP7B* gene mutation is in the background of the excessive copper accumulation which is fatal without treatment. More than 550 disease-causing mutations of the gene located at chromosome 13q14.3-q21.1 consisting of 21 exons have been identified \[[@B1]\].

The geographical distribution of the mutations of the*ATP7B* gene is inhomogeneous \[[@B2]--[@B5]\]. In Hungary the p.His1069Gln mutation is the most frequent one with 71% prevalence among the patients \[[@B6]\].

The variable clinical presentation of WD may cause a real diagnostic challenge. The suspicion of the disease usually arises when hepatic or neurologic-psychiatric symptoms appear. Low ceruloplasmin level and presence of Kayser-Fleischer ring could support the diagnosis, but in many cases only genetic testing could confirm it. Genetic investigation of asymptomatic siblings has an extreme importance, since the early treatment could prevent the manifestation of the disease \[[@B7]\]. In acute liver failure urgent genetic testing of all known mutations may strengthen the diagnosis of Wilson\'s disease.

The emergence of next-generation sequencing (NGS) provides a time-saving, cost-effective method for full sequencing of the whole*ATP7B* coding sequence compared to the traditional Sanger sequencing. The NGS technology is based on the detection of a signal during the synthesis of the DNA strand, and therefore the synthesis does not need to be terminated for the perception. On the other hand, several DNA strands can be examined simultaneously \[[@B8]\].

This is the first report on the clinical use of NGS to examine*ATP7B* gene in WD patients including doubtful cases. We used Ion Torrent Personal Genome Machine in heterozygous patients for the identification of the other mutations and also in patients with no known mutation including one with acute on chronic liver failure.

2. Materials and Methods {#sec2}
========================

The method we used for the genetic testing has been previously published by our group for screening of neurofibromatosis type 1 gene \[[@B9]\].

2.1. Biological Samples and DNA Isolation {#sec2.1}
-----------------------------------------

Six (five male and one female) WD patients, four heterozygous for*ATP7B* p.His1069Gln mutation identified by fast PCR test and two with unknown mutation, were selected for this study. The patients were diagnosed and treated at the 1st Department of Internal Medicine, Semmelweis University, Budapest. The diagnosis was based on the international WD score system published in 2003 \[[@B10]\], and each patient had 4 or more scores. The study was approved by the Semmelweis University\'s Committee of Research Ethics and was conducted in accordance with the Helsinki Declaration. All patients gave written informed consent.

Genomic DNA was isolated from 200 *μ*L of peripheral blood using ReliaPrep Blood gDNA Miniprep System (Promega, Madison, WI). Briefly, the blood samples were digested with Proteinase K solution in the presence of Cell Lysis Buffer, and, after 10 min of incubation at 56°C, DNA was bound to ReliaPrep Binding Column. After three washes, DNA was eluted into 50 *μ*L of nuclease-free water. The concentration of the isolated DNA was determined with Qubit dsDNA HS Assay Kit (Life Technologies, Carlsbad, CA).

2.2. Ion Torrent Sequencing {#sec2.2}
---------------------------

*ATP7B* (21 coding exons) amplicons were designed using the AmpliSeq Designer software (Life Technologies, CA, USA), targeting the complete coding sequence of*ATP7B* gene, resulting in a total of 55 amplicons. To gain a higher coverage of the coding exons, we designed the primers to also flank some parts of the introns. Amplicon library was prepared using the Ion AmpliSeq Library Kit 2.0 (Life Technologies, CA, USA); briefly, multiplex primer pools were added to 10 ng of genomic DNA and amplified with the following PCR cycles: at 99°C for 2 min, at 99°C for 15 s, and at 60°C for 4 min (18 cycles), and holding on at 10°C. Primers were partially digested using a FuPa reagent, and then sequencing adapters were ligated to the amplicons. The library was purified in multiple times using the Agencourt AMPure XP Reagent (Beckmann Coulter, CA, USA). The concentration of the final library was determined by fluorescent measurement on Qubit 2.0 instrument (Life Technologies, CA, USA). Template preparation was performed with Ion OneTouch kit (Life Technologies, CA, USA) on semiautomatic Ion OneTouch instrument using an emPCR method. After breaking the emulsion, the nontemplated beads were removed from the solution during the semiautomatic enrichment process on Ion OneTouch ES (Life Technologies, CA, USA) instrument. After adding the sequencing primer and polymerase, the fully prepared Ion Sphere Particle (ISP) beads were loaded into an Ion 314 v2 sequencing chip, and the sequencing runs were performed using the Ion PGM 200 Sequencing kit v2 (Life Technologies, CA, USA) with 500 flows.

2.3. Sanger Sequencing Validation {#sec2.3}
---------------------------------

The PCR primers were designed using Primer3Plus (<http://primer3plus.com/>) software. Roche FastStart TaqMan Probe Master (Roche) kit was used to amplify the target regions and the PCR program was as follows: 95°C for 10 min, 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 45 s, and the final step was 72°C for 5 min. PCR products were enzymatically cleaned using ExoSAP IT (Affymetrix, Santa Clara, CA) according to the manufacturer\'s instructions. Sanger sequencing was performed using BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies) using an ABI 3130 instrument (Life Technologies).

2.4. Data Analysis {#sec2.4}
------------------

Data from the Ion Torrent runs were analyzed using the platform-specific pipeline software Torrent Suite v3.6 for base calling, trim adapter and primer sequences, filter out poor quality reads, and demultiplex the reads according to the barcode sequences. Briefly, TMAP (<https://github.com/iontorrent/TMAP>) algorithm was used to align the reads to the hg19 human reference genome, and then the variant caller plug-in was selected to run to search for germ line variants in the targeted regions. The variant caller algorithm parameters were more relaxed to avoid false negative cases. Integrative Genomics Viewer was used for visualization of the mapped reads. Variants were reviewed and annotated using dsSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>) and Wilson Disease Mutation Database (<http://www.wilsondisease.med.ualberta.ca/index.asp>). For variant interpretation, Ingenuity Variant Analysis Pipeline (Ingenuity, Rewood City, CA) was also used. Pathogenic status of the variant was stated if it was a missense variant with \<1% minor allele frequency and/or the variant was listed in the literature or in the databases as a pathogenic alteration. All of the deleterious variants were confirmed by Sanger sequencing. The Sanger sequence data were investigated using ABI Sequence Scanner 1.0 (Life Technologies) and BioEdit (<http://www.mbio.ncsu.edu/bioedit/bioedit.html>) software.

3. Results {#sec3}
==========

The demographic and clinical characteristics of the patients are shown in [Table 1](#tab1){ref-type="table"}. One patient without known mutation was critically ill with acute on chronic liver disease. The typical laboratory findings (ALT 90, AST 178, ALP 88, and bilirubin 247) proposed Wilson\'s disease. The diagnosis was strengthened by genetic testing making possible the liver transplantation via Eurotransplant program in*Patient 5* with acute on chronic liver failure.

In each case, the diagnosis of Wilson\'s disease was confirmed by identifying the mutations in both alleles. The results were available within 48 hours.

The average read number per sample was 134386, with an average 1X on-target coverage of 99.46%. The mean raw accuracy was 99.2%. The average base coverage depth was 1883 ([Table 2](#tab2){ref-type="table"}). The number of identified variants per sample was between 8 and 13; however most of them were known as non-disease-causing variants.

Overall, we found nine disease-causing variants. The most frequent mutation was p.His1069Gln (exon 14, ATP loop) detected in four patients. One novel missense mutation (p.Ala1270Ile, exon 18, ATP hinge vide [Figure 1](#fig1){ref-type="fig"}) and three well-known missense mutations (p.Arg969Gln, exon 13, TM6; p.Ala1063Val, exon 14, ATP loop, and p.Leu1305Pro, exon 19 bet ATP hinge/TM7), three frame-shift mutations (c1707+2dupT, exon 4, Cu6; p.Met769-fs exon 8 TM4, and p.Ala1135-fs exon 15 ATP loop), and one nonsense mutation (p.Gln1351Stop, exon 20, TM8) were detected. All of these variants had been validated by Sanger sequencing.

4. Discussion {#sec4}
=============

Although there is an international diagnostic score system for WD \[[@B10]\], the set-up of the diagnosis remains a great challenge in many cases. The signs and symptoms are very colorful, and most of the criteria have relatively low sensitivity and/or specificity. Although genetic testing in itself can ascertain the diagnosis, it is limited by the great variety of the mutations. It is also difficult to screen the siblings of a WD patient, especially of those who do not have identified mutations, since the abnormal laboratory results of copper metabolism may occur in heterozygous carriers. The tight observation of these siblings and the doubt if they are affected can make their life very stressful and uncomfortable. The detection of the mutations in the index patient and searching for the same in the siblings can resolve this problem.

The whole gene analysis of*ATP7B* by PCR and capillary sequencing in a large cohort of WD patients has been recently published \[[@B11]\]. According to our knowledge based on PubMed data this is the first report on next-generation sequencing of the*ATP7B* gene for genetic diagnosis of Wilson\'s disease in a clinical setting. Since the disease-causing mutations may occur in the whole length of the gene and every exon could be affected, the genetic examination by classical methods is ponderous and time-consuming.

Our study clearly shows the great benefit of NGS. The compound heterozygosity has been proved in each patient within a very short examination time. Previously, we published that p.His1069Gln mutation is most common one in Hungary (71%) similar to other Central and Eastern European countries \[[@B6], [@B12]--[@B14]\]. Results of this study are in concordance with the former epidemiological data, since this mutation was confirmed in the majority of the cases, in 4 out of 6. Among the eight other mutations we found, there is one novel mutation in exon 18 which is a missense mutation causing an asparagine-isoleucine change in the transporter. Interestingly, the mutations beyond p.His1069Gln occurred only in one allele of a single patient.

However, it is already well known that p.His1069Gln homozygous mutation tends to relate with neurological symptoms; the effect of other infrequent mutations on the phenotype is hard to be examined due to the low number of cases (vide [Table 1](#tab1){ref-type="table"}) \[[@B15]\].

p.Ala1063Val mutation detected in one patient who has been diagnosed with WD prior to genetic testing is thought to be a non-disease-causing variant according to the Wilson Disease Mutation Database, although only one publication suggested that it might be a polymorphism \[[@B4]\]. On the other hand, subsequent data show that it might be a variant of unknown significance (VUS) \[[@B16]\]. Furthermore it was the one and only nucleotide change in a WD family analyzed by Loudianos et al. \[[@B17]\]. Overall it seems that p.Ala1063Val mutation still might be associated with Wilson\'s disease.

NGS gave a tremendous benefit for a 47-year-old patient with acute on chronic liver failure. Although nearly all patients with ALF due to Wilson\'s disease are potentially diagnosed (or suspicion is very high) with use of simple biochemical and laboratory criteria (ratio of alkaline phosphatase to bilirubin, ratio of AST to ALT, and Coombs negative hemolytic anemia) \[[@B18]\], the diagnosis may require an urgent genetic testing of all mutations. In some patients the laboratory data alone cannot give enough scores in the international score system \[[@B10]\], which is required by Eurotransplant program for donor liver allocation. In our case, the results of D-penicillamine test and the NGS arrived simultaneously, confirming Wilson\'s disease. According to the actual regulation of Eurotransplant Organization in case of acute on chronic liver failure only WD and Budd-Chiari syndrome are accepted as indication for urgent transplantation. Identifying mutations in both alleles gave a clear-cut evidence of the disease despite lack of Kayser-Fleischer ring, lack of neurological symptoms, and p.His1069Gln mutation. Thanks to the quick diagnosis the patient has been transplanted within two days and survived, and he is still in good condition one year later.

5. Conclusion {#sec5}
=============

According to our results we found next-generation sequencing to be a very useful, reliable, time-saving, and cost effective method for diagnosing Wilson\'s disease in selected cases.
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![The identified mutations of patient 5. Both c.3809A\>T (causing amino acid change p.Ala1270Ile) and c.1707+2dupT mutations are confirmed by Sanger-sequencing. The 3809A\>C and A\>G mutations are known, but the A\>T substitution is a novel alteration at this position. (a1) Visualizing the alignment of the sequencing reads covering the*ATP7B* c.3809A\>T heterozygous point mutation. The coverage was 400-fold (211-fold reference and 189-fold variant coverage). (b1) Validating our finding with Sanger sequencing, red arrow indicates the position of the point mutation. The mutation is present in both directions. (a2) Visualizing the alignment of the sequencing reads covering the*ATP7B* c.1707+2dupT heterozygous insertion mutation. The coverage was 399-fold (188-fold reference and 211-fold variant coverage). (b2) Validating our finding with Sanger-sequencing, red arrow indicates the position of the insertion. The mutation is present in both directions.](GRP2016-4548039.001){#fig1}

###### 

Demographic and clinical characteristics of the patients.

              Gender    Age at onset (year)   KFR   Neu   HA   Urin Cu   Biopsy   Cerul (g/L)   *ATP7B* status               WD score^a^   Phenotype
  ----------- --------- --------------------- ----- ----- ---- --------- -------- ------------- ---------------------------- ------------- -----------
  Patient 1    Female   12                    P     A     A    ++        ND       0.18          p.Met769-fs/p.His1069Gln     6             S
  Patient 2   Male      17                    A     P     A    \+        ND       0.05          p.Ala1063Val/p.His1069Gln    6             N1
  Patient 3   Male      8                     P     A     A    ++        \+^b^    0.06          p.His1069Gln/p.Gln1351Stop   8             H2
  Patient 4   Male      17                    P     A     A    \+        ND       0.03          p.Ala1135-fs/p.Leu1305Pro    5             H2
  Patient 5   Male      44                    A     A     A    ++        ND       0.08          p.Ala1270Ile/c.1707+2dupT    4             H1
  Patient 6   Male      14                    P     P     A    ND        ND       0.04          p.Arg969Gln/p.His1069Gln     7             N2

KFR: Kayser-Fleischer ring; Neu: neurological signs and/or CT/MRI alterations; HA: hemolytic anemia; Urin Cu: urinary copper, 1-2X ULN: +, \>2x ULN or positive D-penicillamine challenge: ++; Cerul: ceruloplasmin, P: present; A: absent; ND: not done; S: sibling; H1: acute liver failure; H2: chronic liver disease; N1: neurological symptoms with liver disease; N2: only neurological symptoms.

^a^According to the international score system, 4 or more scores, diagnosis of WD is highly likely. ^b^Rhodanine positivity.

###### 

Per sample and per amplicon coverage data.

  Chromosome   Amplicon start   Amplicon end   Amplicon ID      Gene ID                       Patient 1   Patient 2   Patient 3   Patient 4   Patient 5   Patient 6
  ------------ ---------------- -------------- ---------------- ----------------------------- ----------- ----------- ----------- ----------- ----------- -----------
  chr13        52520358         52520440       AMPL1102520485   ATP7B                         812         484         378         9467        3557        3275
  chr13        52542530         52542653       AMPL1102672008   ATP7B                         951         390         145         3149        5510        3183
  chr13        52538909         52539030       AMPL1404436522   ATP7B                         9           2           2           2           4           46
  chr13        52523735         52523838       AMPL561308261    ATP7B                         417         285         89          245         683         2611
  chr13        52518244         52518356       AMPL561308388    ATP7B                         1140        520         339         7934        6166        3595
  chr13        52516492         52516613       AMPL561312436    ATP7B                         600         309         70          1510        3218        2152
  chr13        52515134         52515253       AMPL561312709    ATP7B                         799         287         74          1340        3258        2733
  chr13        52520435         52520563       AMPL561312859    ATP7B                         622         308         149         409         906         2130
  chr13        52511616         52511742       AMPL561313522    ATP7B                         343         233         58          1462        2168        1069
  chr13        52548475         52548562       AMPL561315457    ATP7B                         740         557         248         660         1251        3869
  chr13        52548014         52548135       AMPL561316164    ATP7B                         506         109         93          244         614         3077
  chr13        52535952         52536073       AMPL561319098    ATP7B                         345         332         62          1845        3919        1350
  chr13        52532445         52532575       AMPL561319439    ATP7B                         495         382         75          260         477         2421
  chr13        52518332         52518433       AMPL561320185    ATP7B                         445         574         270         852         1305        2147
  chr13        52511401         52511536       AMPL561321003    ATP7B                         899         422         181         3036        4216        2756
  chr13        52523839         52523934       AMPL561322321    ATP7B                         802         389         181         3872        3781        2867
  chr13        52520556         52520638       AMPL561322791    ATP7B                         836         630         362         9187        4465        3540
  chr13        52534277         52534394       AMPL561324803    ATP7B                         670         295         126         3402        3937        2458
  chr13        52542654         52542747       AMPL561326888    ATP7B                         755         503         272         811         1791        3775
  chr13        52524407         52524535       AMPL561327019    ATP7B                         215         139         38          126         250         1023
  chr13        52516614         52516708       AMPL561328057    ATP7B                         546         401         206         591         1259        2779
  chr13        52515254         52515365       AMPL561328062    ATP7B                         768         466         191         508         1239        3144
  chr13        52513223         52513345       AMPL561328524    ATP7B                         454         382         113         239         732         1771
  chr13        52548563         52548672       AMPL561329883    ATP7B                         836         384         149         3334        4618        3056
  chr13        52511743         52511824       AMPL561330934    ATP7B                         718         556         323         946         1461        3040
  chr13        52532576         52532683       AMPL561335846    ATP7B                         671         433         227         5882        4370        2749
  chr13        52511497         52511615       AMPL561335849    ATP7B                         813         494         353         857         1761        3297
  chr13        52549016         52549114       AMPL561337443    ATP7B                         453         347         167         3818        3121        2050
  chr13        52534395         52534476       AMPL561338245    ATP7B                         734         542         476         1282        2378        2732
  chr13        52539048         52539119       AMPL561339230    ATP7B                         532         448         394         9393        3563        2527
  chr13        52544567         52544690       AMPL561342268    ATP7B                         806         449         130         2523        3519        2674
  chr13        52548673         52548782       AMPL561343055    ATP7B                         512         446         158         513         1052        3022
  chr13        52548136         52548260       AMPL561345064    ATP7B                         826         442         128         2692        4578        2624
  chr13        52549115         52549227       AMPL561347059    ATP7B                         469         369         144         398         771         2612
  chr13        52539120         52539203       AMPL561347740    ATP7B                         787         737         877         3031        2553        4243
  chr13        52509711         52509847       AMPL561353128    ATP7B                         329         280         70          208         669         2063
  chr13        52549228         52549346       AMPL561354995    ATP7B                         720         232         59          900         2717        2418
  chr13        52508853         52508964       AMPL561358361    ATP7B                         660         455         181         4930        3832        2325
  chr13        52548783         52548894       AMPL561361353    ATP7B                         1286        639         267         7815        7277        3588
  chr13        52544691         52544813       AMPL561365512    ATP7B                         542         354         150         336         898         2919
  chr13        52508959         52509084       AMPL561366430    ATP7B                         694         574         217         630         1344        2208
  chr13        52524093         52524178       AMPL561367088    ATP7B                         368         315         5           31          82          2778
  chr13        52524179         52524298       AMPL561373391    ATP7B                         725         390         108         2697        4100        2724
  chr13        52544814         52544931       AMPL561373418    ATP7B                         235         52          34          618         1093        1651
  chr13        52548893         52549018       AMPL561375011    ATP7B                         498         471         103         239         550         2166
  chr13        52509084         52509181       AMPL561375394    ATP7B                         719         461         144         5037        3879        2163
  chr13        52531644         52531756       AMPL561379526    ATP7B                         512         234         80          1601        2656        2155
  chr13        52548255         52548381       AMPL561399016    ATP7B                         467         446         98          286         676         2965
  chr13        52548382         52548474       AMPL561401395    ATP7B                         247         124         69          1000        357         2414
  chr13        52513106         52513229       AMPL561308165    c.3699+27T\>C, ATP7B          560         372         88          1778        3799        2176
  chr13        52585387         52585514       AMPL561308108    c.-36C\>T, c.-75A\>C, ATP7B   294         287         110         313         616         2859
  chr13        52585831         52585931       AMPL1275480480   ATP7B                         493         397         129         807         780         1389
  chr13        52585851         52585971       AMPL1275480698   ATP7B                         458         140         55          1205        1642        811
  chr13        52534093         52534223       AMPL1275484758   ATP7B                         140         230         35          69          187         2149
  chr13        52585478         52585613       AMPL561317674    ATP7B                         560         186         58          997         1619        1979
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